Ehemaliger Geschäftsführer und Unternehmensgründer, Vorstandsvorsitzender und Aufsichtsratsmitglied der Syngenta AG
Mitglied des Verwaltungsrats seit : 2009
Ende des aktuellen Mandats: HV 2021
Zahl der von VINCI gehaltenen Eigenaktien: 1.027 zum 31. 12. 2018
Alter: 72 Jahre
Director considered independent by the Board of Directors.
Mandate in nicht börsennotierten Unternehmen oder sonstigen Organisationen
Zum 31. 12. 2018 ausgeübte Mandate
In den letzten fünf Geschäftsjahren ausgelaufene Mandate
Member of the Board of Directors of Insead; Chairman of the Council of Trustees of Cancer Research UK.
Weitere Sachkompetenzen und berufliche Erfahrung
Michael Pragnell is a graduate of Oxford and Insead. Following a period in the international department of the First National Bank of Chicago in New York, Mr Pragnell held a series of positions in the Courtaulds group from 1975 until 1995: Chief Executive Officer of National Plastics (1985-1986), Chief Executive Officer of International Paint plc (1986-1992) and Chief Financial Officer (1992-1994) of Courtaulds plc, where he was appointed to the Board of Directors in 1990. From 1995 to 2000, he was Chief Executive Officer of Zeneca Agrochemicals and a member of the Executive Committee of Zeneca plc (now known as AstraZeneca plc), and was appointed to its Board of Directors in 1997. From 2000 to 2007, Mr Pragnell was the founding Chief Executive Officer and Chairman of the Executive Committee of Syngenta AG, where he was also a member of the Board of Directors from its creation. Other positions held include being a member of the Board of Directors of David S. Smith (now DS Smith) plc from 1996 to 1999 and of Advanta BV (Netherlands). He was Chairman of CropLife International from 2002 to 2005 and served as Chairman of the Council of Trustees of Cancer Research UK from 2010 to 2016. Mr Pragnell was awarded a CBE in the UK’s 2017 New Year’s Honours List.